TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02542852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg
Description: Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
Study: NCT04609618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Appscent Device
Description: computer-controlled, low pressure compressed air based, with disposable odorant capsules solution provided an odor environment at the nose,
Study: NCT01839578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)
Description: Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~* 4% trisodium citrate solution~* Calcium chloride solution (100 mmol/L)~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~* Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~* Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~* Blood flow adapted to the acid-base status

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)
Description: Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~* Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~* Standard dialysate for CRRT : Prismasol® K2 solution~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of
Study: NCT02929485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Tolcapone 200mg (single dose) administered at study visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (200mg) administered at study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
Study: NCT03161990

Intervention type: PROCEDURE
Intervention: Transgluteal approach to the hip joint
Description: Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.

Intervention type: PROCEDURE
Intervention: Posterior approach to the hip joint
Description: Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
Study: NCT01059877

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1072nm infrared Photobiomodulation
Description: 1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation SIMULATED
Description: Device mounted and procedure followed but with no stimulation.
Study: NCT00639002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 25 mg
Description: Ruxolitinib was supplied as 5 and 25 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 40 mg
Description: Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
Study: NCT05153135

Intervention type: DRUG
Intervention: Ribociclib
Description: Participants who initiated CDK4/6i therapy

Intervention type: DRUG
Intervention: Palbociclib
Description: Participants who initiated CDK4/6i therapy

Intervention type: DRUG
Intervention: Abemaciclib
Description: Participants who initiated CDK4/6i therapy
Study: NCT03950869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectation Manipulation
Description: Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase positive expectations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Expectation Manipulation
Description: Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase negative expectations.
Study: NCT00745446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm Venous Occlusion Plethysmography
Description: Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm Venous Occlusion Plethysmography
Description: Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm Venous Occlusion Plethysmography
Description: Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
Study: NCT04191486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-817MA
Description: 224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT01430611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A and C) Polysaccharide Vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A and C) Polysaccharide Vaccine
Description: 0.5 mL, Subcutaneous
Study: NCT01245452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (8 mg/kg monthly from week 0 to 20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
Study: NCT06175572

Intervention type: DEVICE
Intervention: coronary physiological indices
Description: coronary physiological indices

Intervention type: DEVICE
Intervention: coronary physiological indices
Description: coronary physiological indices

Intervention type: DEVICE
Intervention: coronary physiological indices
Description: coronary physiological indices

Intervention type: DEVICE
Intervention: coronary physiological indices
Description: coronary physiological indices
Study: NCT00886145

Intervention type: DEVICE
Group type: OTHER
Intervention: Vibration: Right Leg and No Vibration: Left Leg.
Description: Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.
Study: NCT04674449

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Disclosure of IDP results
Description: The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: IDP performed but results not disclosed
Description: The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
Study: NCT00743470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: lopinavir/ritonavir tablet; see arm for intervention description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin
Description: rifabutin capsule; see arms for intervention description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin
Description: rifabutin capsule; see arms for intervention description
Study: NCT00841633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induced hypertension with norepinephrine
Description: Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
Study: NCT00765973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Liposomes Injection (TLI)
Description: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Liposomes Injection (TLI)
Description: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
Study: NCT01996306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU Infusion
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-LV (dl-LV)
Description: 200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11 (Irinotecan)
Description: 150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
Study: NCT01441921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pistachios
Description: Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control diet
Description: Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months.
Study: NCT03806179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 MBq/kg Betalutin
Description: 10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 MBq/kg Betalutin
Description: 15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
Study: NCT02307669

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INCA feedback
Description: The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines.
Study: NCT00304265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)
Description: 0.5 mL, Intramuscular
Study: NCT01820078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
Study: NCT02553460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITMHA
Description: Given intrathecally (IT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or naso-gastrically (NG) or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia Chrysanthemi
Description: Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
Study: NCT01820078

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator Arm
Description: Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator Arm
Description: Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
Study: NCT02553460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Taken PO or NG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.
Study: NCT03104621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride (BAK)
Description: Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride (BAK)
Description: Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.0015% tafluprost
Description: Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.0015% tafluprost
Description: Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
Study: NCT02406794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular taping
Description: The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
Study: NCT02166034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: garden intervention
Description: The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
Study: NCT01622608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine Information Kiosk
Description: The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
Study: NCT01119807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous access during OHCA
Description: First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humeral IO insertion
Description: First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIbial IO insertion
Description: First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
Study: NCT03382431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC786
Description: Repeat doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/vehicle
Description: Repeat doses
Study: NCT00444236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo for active drug
Study: NCT02553460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO or NG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, IM or PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Leucovorin rescue PO or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV.
Study: NCT02044523

Intervention type: DEVICE
Intervention: Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
Description: Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
Study: NCT00521833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
Study: NCT02847117

Intervention type: OTHER
Group type: OTHER
Intervention: Mastiha
Description: The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
Study: NCT01026636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Study: NCT01094405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Epstein-Barr Virus (EBV) Vaccine
Study: NCT04705922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 Capsule
Description: TT-00420 capsule formulation, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 Capsule
Description: TT-00420 capsule formulation, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 Capsule
Description: TT-00420 capsule formulation, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 Tablet
Description: TT-00420 tablet formulation, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 Tablet
Description: TT-00420 tablet formulation, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 Tablet
Description: TT-00420 tablet formulation, administered orally
Study: NCT00212056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANP(hANP)
Description: 0∙025 μg/kg per min for 3 days(intravenous)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: placebo